Biocat and the UB Cell Therapy Program organize workshop 'Challenges and Risks of Research in Advanced Therapies' in Barcelona
More than 100 scientists, companies and professionals will share their point of view on how to seek out joint work lines.
BY BIOCAT
Biocat and the Cell Therapy Program of the University of Barcelona Faculty of Medicine (TCUB) are organizing a workshop entitled Challenges and Risks of Research in Advanced Therapies on 20 January 2012 in Barcelona in order to analyze the current state of this field of biomedicine and its outlook for the future. Advanced therapies is part of regenerative medicine, an emerging field that offers new opportunities to treat illnesses caused by a loss of cell function. These are very new methods that, in most cases, are still in the experimental stages.
The Esther Koplowitz Center (CEK) for Biomedical Research —located next to Hospital Clínic— will welcome more than 100 scientists, professionals and companies from the sector in order to delve deeper into three different aspects: the research itself, types and use of these therapies in hospital centers, and regulatory issues associated with clinical research and its therapeutic use.
Advanced therapies is an emerging field that offers new opportunities to treat illnesses caused by a loss of cell function.
The workshop will be inaugurated by Dr. Montserrat Vendrell, CEO of Biocat; Dr. Marta Aymerich, head of Healthcare Research and Innovation for the Catalan Health Department Directorate General for Healthcare Regulation, Planning and Resources; Dr. Jordi Alberch, associate Dean for Research of the University of Barcelona, and Dr. Francesc Cardellach, dean of the University of Barcelona Faculty of Medicine. Speakers will include Dr. Josep Maria Canals, coordinator of the TCUB; Dr. Agustín Zapata, professor of Cell Biology at the Complutense University of Madrid; Dr. Anna Serrano, staff scientist at the Barcelona Biomedical Research Institute-CSIC; Dr. Dirk Büscher, CEO of Gri-Cel (Grifols group); Dr. Felipe Prosper, director of the Hematology Service and of the Cell Therapy Area at the University Clinic of Navarra; Dr. Joan García, director of the XCelia Advanced Therapies Division of the Blood and Tissue Bank of Catalonia; Dr. Maria Pascual, VP Regulatory Affairs for TiGenix, and Dr. Begoña Aran, Tissue and Cell coordinator for the Catalan Transplant Organization (OCATT).
The speakers will cover a variety of topics, including the current state and future outlook for research in advanced therapies and their development and integration into the healthcare system; key elements in the development of drugs from advanced therapies; and the questions posed for legislation in this arena, among others.
This session is part of the sectorial events Biocat organizes periodically focusing on an emerging topic of science or technology that is of particular interest to the community, and in which professionals can discover new approaches and discuss their experiences and points of view.
The University of Barcelona Cell Therapy Program is home to translational stem-cell and regenerative medicine biomedical research teams from the Faculty of Medicine. These teams work in different areas of medicine like neurology and the musculoskeletal system; diabetes and metabolism; cardiology; hemato-oncology; ophthalmology; and pneumology. International benchmark research centers IDIBAPS and IDIBELL also participate in the TCUB, as does the Barcelona Hospital Clínic.
Dia: 20 de gener de 2012
Hora: de 9:15 h a 14:00 h
Lloc: Esther Koplowitz Center (CEK) for Biomedical Research • Esteve Auditorium • C/ Rosselló, 149-153 • Barcelona (map)
Registration closed.
Questions: innovacio@biocat.cat
- Press release in Spanish (20/1/2012)
- Recommended article: Challenges and risks of research in advanced therapies (Dr. Josep M. Canals, March 2012)
| Organized by: |
  |
| With the support from: |
   |